"Rx") pharmaceuticals, nutritional products and active pharmaceutical ingredients ("API") and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as certain other markets throughout the world, including Canada, China and Latin America. Visit Perrigo on the Internet (
http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company'
'/>"/>
SOURCE Perrigo Company Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine technology :1.
Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 20122.
Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance3.
Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference4.
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules5.
Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream6.
Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension7.
Perrigo Company To Present At The William Blair Growth Stock Conference8.
Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%9.
Perrigo Company Announces Quarterly Dividend10.
Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference11.
Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million